


Please Direct All Correspondence to Customer Number **30313**



**TRANSMITTAL LETTER  
INFORMATION DISCLOSURE STATEMENT**


Applicant : Botstein, et al.  
App. No : 10/692,072  
Filed : October 22, 2003  
For : SECRETED AND TRANSMEMBRANE  
POLYPEPTIDES AND NUCLEIC ACIDS  
ENCODING THE SAME  
Examiner : Fredman, Jeffrey  
Art Unit : 1637

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

May 18, 2005

(Date)


  
AnneMarie Kaiser, Reg. No. 37,649


**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
  - (X) Listing 38 references.
  - (X) Enclosing 25 references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

  
AnneMarie Kaiser  
Registration No. 37,649  
Attorney of Record  
Customer No. 30,313  
(619) 235-8550



## INFORMATION DISCLOSURE STATEMENT


Applicant : Botstein, et al.  
App. No : 10/692,072  
Filed : October 22, 2003  
For : SECRETED AND  
TRANSMEMBRANE POLYPEPTIDES  
AND NUCLEIC ACIDS ENCODING  
THE SAME  
Examiner : Fredman, J.  
Art Unit : 1637

## CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

May 18, 2005

(Date)

  
AnneMarie Kaiser, Reg. No. 37,649

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is an Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing 38 references to be considered by the Examiner. Also enclosed are 25 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: May 18, 2005

By: 

AnneMarie Kaiser  
Registration No. 37,649  
Attorney of Record  
Customer No. 30,313  
(619) 235-8550



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Multiple sheets used when necessary)	Application No.	10/692,072
	Filing Date	October 22, 2003
	First Named Inventor	Botstein, et al.
	Art Unit	1637
SHEET 1 OF 3	Examiner	Fredman, J.
	Attorney Docket No.	GNE.2930R1C10C1

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	6,025,156	02-15-2000	Gwynn, et al.	
	2	6,124,433	09-26-2000	Falb, et al.	
	3	6,156,500	12-05-2000	Falb, Dean	
	4	6,162,604	12-19-2000	Jacob, Chaim O.	
	5	6,228,582	05-08-2001	Rodier, et al.	
	6	6,395,306	05-28-2002	Cui, et al.	
	7	6,414,117	07-02-2002	Levinson, D. A.	
	8	6,465,185	10-15-2002	Goldfine, et al.	
	9	6,498,235	12-24-2002	Sheppard, et al.	
	10	6,562,343	05-13-2003	Levinson, D. A.	
	11	6,645,499	11-11-2003	Lal, et al.	
	12	6,730,502	05-04-2004	Van Hijum, et al.	
	13	6,737,522	05-18-2004	Sundick, et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
	14	WO 97/38085	10-16-1997	California Pacific Medical Center		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	15	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell</i> , 3rd Edition, pp. 403-404, 453. New York: Garland Publishing.	
	16	ALBERTS, et al. 2002. <i>Molecular Biology of the Cell</i> 4th Edition, pp. 302, 363-364, 379, 435. New York: Garland Publishing.	
	17	ALITALO 1984. Amplification of cellular oncogenes in cancer cells. <i>Med. Biol.</i> , 62:304-317	
	18	BANHASSY, et al. 2004. Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients. <i>BMC Gastroenterology</i> , 4:22-34.	

Examiner Signature	Date Considered
--------------------	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Multiple sheets used when necessary)	Application No.	10/692,072
	Filing Date	October 22, 2003
	First Named Inventor	Botstein, et al.
	Art Unit	1637
	Examiner	Fredman, J.
SHEET 2 OF 3	Attorney Docket No.	GNE.2930R1C10C1

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	19	BIECHE, et al. 1998. Novel Approach to Quantitative Polymerase Chain Reaction Using Real-Time Detection: Application to the Detection of Gene Amplification in Breast Cancer. <i>Int. J. Cancer</i> . 78:661-666.	
	20	BLANCATO, et al. 2004. Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, <i>in situ</i> hybridization and immunohistochemical analyses. <i>British Journal of Cancer</i> , 90(8), 1612-1619.	
	21	GRIMALDI, et al. 1989. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. <i>Blood</i> , 73(8):2081-2085.	
	22	GYGI, et al. Mar. 1999. Correlation between Protein and mRNA Abundance in Yeast. <i>Molecular and Cellular Biology</i> , 1720-1730.	
	23	HANNA, et al. Aug. 1999. HER-2/neu breast cancer predictive testing. <i>Pathology Associates Medical Laboratories</i> .	
	24	HEID, et al. 1996. Real Time Quantitative PCR. <i>Genome Res</i> . 6:986-994.	
	25	HIGUCHI, et al. April 1992. Simultaneous Amplification and Detection of Specific DNA Sequences. <i>Biotechnology</i> , 10:413-417.	
	26	HYMAN et al. Nov. 2002. Impact of DNA Amplification of Gene Expression Patterns. <i>Cancer Research</i> , 62:6240-6245.	
	27	LEWIN, B. 1994. Oncogenes: Gene Expression and Cancer, Chap. 39, pp.1196-1201. <i>Genes V</i> . New York: Oxford University Press.	
	28	LEWIN, B. 1997. Regulation of Transcription, Chap. 29, pp. 847-848. <i>Genes VI</i> . New York: Oxford University Press.	
	29	LIVAK, et al. 1995. Oligonucleotides with Fluorescent Dyes at Opposite Ends Provide a Quenched Probe System Useful for Detecting PCR Product and Nucleic Acid Hybridization. <i>PCR Methods Appl</i> 4:357-362.	
	30	MEEKER, et al. 1990. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. <i>Blood</i> , 76(2):285-289.	
	31	MERIC, et al. 2002. Translation initiation in cancer: A novel target for therapy. <i>Molecular Cancer Therapeutics</i> , 1:971-979.	
	32	MERLINO, et al. 1985. Elevated Epidermal Growth Factor Receptor Gene Copy Number and Expression in a Squamous Carcinoma Cell Line. <i>J. Clin. Invest.</i> , 75:1077-1079	
	33	ØRNTØFT, et al. 2002. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. <i>Molecular &amp; Cellular Proteomics</i> , 1:37-45.	
	34	PENNICA, et al. 1998. WISP genes are members of the connective tissue growth factor family that are up-regulated in Wnt-1 transformed cells and aberrantly expressed in human colon tumors. <i>Proc. Natl. Acad. Sci. USA</i> . 95(25):14717-14722.	
	35	PITTI, et al., 1998. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. <i>Nature</i> . 396(6712):699-703.	

Examiner Signature	Date Considered
--------------------	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Multiple sheets used when necessary)

SHEET 3 OF 3

Application No.	10/692,072
Filing Date	October 22, 2003
First Named Inventor	Botstein, et al.
Art Unit	1637
Examiner	Fredman, J.
Attorney Docket No.	GNE.2930R1C10C1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	36	POLLACK, et al. 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. <i>PNAS</i> , 99(20):12963-12968.	
	37	SINGLETON, et al. 1992. Clinical and pathologic significance of the c-erbB-2 ( <i>HER-2/neu</i> ) oncogene. <i>Pathol. Annu</i> , 1(27):165-190.	
	38	ZHIGANG, et al. 2004. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. <i>World Journal of Surgical Oncology</i> , 2:13.	

1717838  
051805

Examiner Signature

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.